The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.Credit: Reuters/Arnd Wiegmann
Related Topics Health »
ZURICH (Reuters) - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.
Alcon said in a statement on Monday the Simbrinza eye drops suspension had been approved to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
"We are pleased to introduce the only fixed combination therapy without a beta-blocker to help more glaucoma patients manage their progressive eye condition," Jeff George, global head of Alcon, said in the statement.
(Reporting by Silke Koltrowitz; Editing by Kenneth Maxwell)FILED UNDER: Health Tweet this Link this Share this Digg this EmailPrintReprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/Comments (0)Be the first to comment on reuters.com. Add yours using the box above.
View the Original article